Pangea Data, a company aimed at detecting difficult to diagnose diseases in patients, collaborates with Alexion, a subsidiary of AstraZeneca focused on the treatment of rare diseases, to develop together, to validate clinically and ultimately search for regulatory approval for an AI-gel-off range to detect pituitary fatasia in adults.
“A few months ago, Alexion concluded a multi -year cooperation agreement with Pangea, allowing Pangea to configure his product platform to help gaps on care for a rare condition called hypophosphatasia,” “ Vibhor Gupta, founder and CEO of Pangea Data, said MobiHealthNews.
Hypophosphatasia is a rare hereditary disorder that influences the development of bone and can lead to dental loss in affected persons.
The situation disrupts the process of mineralization, whereby minerals such as calcium and phosphorus are deposited in developing bones and teeth, which leads to a shortage of tissue-specific alkaline phosfatase.
Mild forms of the rare genetic disorder influence one in 6,000 to one in 7,000 people, According to the Cleveland Clinic. Serious forms affect one in 100,000 people on one in 300,000 babies who were born every year.
Together, Alexion and Pangea AI and clinical guidelines will use to develop the Artificial Intelligence Clinical Data Support System (AI-CDSS), aimed at accelerating the detection of hypophosphatasia by analyzing information within the electronic health file of a patient (EHR).
As rare diseases can be More challenging for doctors to detectThe time for diagnosis is often longer than for many more well -known disorders.
Gupta said that the dental data of a patient, their journey, family history and basic laboratories, including alkalic phosphatase (Alp) levels, are vital to obtain. However, these are not always immediately available for doctors.
“As a clinicus you have 15,000 or 20,000 disorders difficult to diagnose, and there is a very good chance that you would think about the things you have heard about, talk about the things you know that are not rare circumstances,” Gupta said.
“The idea would be that the technology is configured, validated and then implemented at the point of care, so that clinicians can use it seamlessly in their daily work, instead of having to go to another application or think about what is really going on.
The cooperation between Pangea data and Alexion, which was entered into in March, is in the first phase, where the two companies work with clinicians to define the configuration of the AI-CDS platform.
“We want to get in touch with clinical colleagues who work on pituitary stasia in a large number of health systems in nine countries,” said Gupta.
“The idea is to work with them and adapt to their clinical and business priorities. You close care gaps to improve the results of the patient, but the business priority is also important.”
At this point, the Pangea AI compatform is already able to detect 42 care hives that correspond to 16 disorders that are difficult to diagnose, such as chronic obstructive lung disease (COPD) and ovarian cancer.
Gupta said that as soon as the pituitary-oriented program is used in the EPDs of the health systems, diagnoses will be a fast process-8 to 10 minutes.
“As far as the doctor is concerned, we are practically invisible. They don’t even have to change a tab or switch an application because 10 minutes is a very short time,” he said. “It’s something that will give them results immediately.”
#Exclusive #Pangea #Data #Alexion #Partner #AstraZeneca #spot #rare #diseases #EHRS